13/03/2017
Marie Skłodowska-Curie Actions  SME OFFER

Early Stage Researcher PhD fellowship in the Marie Skłodowska-Curie ITN European Training Network TRANSMIT on “Translating the Role of Mitochondria in Tumourigenesis”

This job offer has expired


  • ORGANISATION/COMPANY
    AvantiCell Science Ltd
  • RESEARCH FIELD
    Biological sciences
    TechnologyBiotechnology
  • RESEARCHER PROFILE
    First Stage Researcher (R1)
  • APPLICATION DEADLINE
    31/05/2017 17:00 - Europe/London
  • LOCATION
    United Kingdom › Ayr
  • TYPE OF CONTRACT
    Temporary
  • JOB STATUS
    Full-time
  • HOURS PER WEEK
    37.5
  • OFFER STARTING DATE
    01/10/2017
  • EU RESEARCH FRAMEWORK PROGRAMME
    H2020 / Marie Skłodowska-Curie Actions
  • REFERENCE NUMBER
    ESR8
  • MARIE CURIE GRANT AGREEMENT NUMBER
    722605

The TRANSMIT network – Translating the Role of Mitochondria in Tumourigenesis – aims to train promising young scientists through research into the intricate metabolic plasticity that transformed [cancer] cells must undergo to survive the adverse microenvironment existing within a growing tumour, and the contribution of oncogenes and tumour suppressors in shaping metabolism of those transformed cells. TRANSMIT will train 11 PhD students in an overarching training programme involving training-by-research, joint courses on technical, scientific and transferrable skills, participation in public scientific events, and an intense intersectional, networking exchange plan. The TRANSMIT consortium encompasses academic institutions, research centres, and SMEs, all with proven experience in higher education and training and state-of-the art scientific and technical expertise and infrastructures.

The research activities implemented in TRANSMIT are aimed at: (1) dissecting the metabolic remodeling in human cancers, placing the focus on the role of mitochondria and linking basic research to the improvement/development of therapeutic strategies; (2) fostering the communication of this emerging field to the patients and their families; (3) design of predictive in vitro assays to assess the therapeutic potential of interventions targeting these cancer-related metabolic aberrations.

Each of the 11 ESRs will be enrolled in the PhD programme of the beneficiary’s organization (the beneficiaries which do not award a PhD will establish agreements with local and international universities that can provide the degree) and will participate in the network’s training activities and work placements at the laboratories of the collaborating academic and industrial partners. In addition, the training programme of the recruited ESRs will be supplemented by regular meetings and workshops within the TRANSMIT network.

The ACS project within TRANSMIT aims to develop novel cancer cell models to test metabolic intervention strategies identified by other project partners. Its main objectives are to create a panel of novel, cell-based, three dimensional, in vitro models displaying the metabolic aberrations of human cancers and to characterize suitable readouts which will be used to identify targets for therapeutic intervention. ACS project outputs shall be the production of a panel of novel cell-based models; validation of the novel systems according to industry-compliant principles of utility, reproducibility and robustness; demonstration of model utility using metabolic intervention strategies developed by consortium partners.

Benefits

The ESR will be contractually employed by “AvantiCell Science Ltd under the company’s terms and conditions of employment. He or she will monthly receive a Living Allowance, a Mobility Allowance and a Family Allowance compliant with the applicable EC Marie Skłodowska-Curie Actions-ITN general conditions (see http://ec.europa.eu/research/participants/data/ref/h2020/wp/2014_2015/main/h2020-wp1415-msca_en.pdf page 49).

Eligibility criteria

Mobility eligibility requirement: The fellow must not have resided in the country where the research training activities will take place for more than 12 months in the 3 years immediately prior to the recruitment date (and not have carried out their main activity (work, studies, etc.) in that country).

Selection process

Application Procedure

The applicant must send the following documents to the email specified before 31st May 2017:

1) an updated CV; the CV must be without gaps, in order to easily check the mobility and experience requirements. CVs that either do not clearly show the applicant’s past experience, or have gaps, will be considered ineligible.

2) a letter giving reason for his/her motivation for the post;

3) at least 1 reference letter (in English) from one former supervisor;

4) the scan of the degree (usually the Master Degree) which would formally entitle him/her to embark on a doctorate, either in the country in which the degree was obtained or in the country in which the researcher will be recruited. In case the degree has not been obtained yet, it is necessary to send a declaration of the university stating that the degree will be obtained before the expected starting date.

 

Applications must be in English and will be evaluated against the following criteria:

- Educational record;

- scientific quality of the applicant’s CV;

- expected individual impact and benefit to the fellow and to the project.

- previous experience in the subject of the TRANSMIT research programme.

Additional comments

AvantiCell Science Ltd (ACS) is a biotechnology Company specialising in cell biology and cell culture technology. The Company was founded in 2006, is profitable, and is presently located in Ayr, South Ayrshire, Scotland.

 

AvantiCell Science’s (ACS) business is founded on the principle that advances in cell culture technology enable the development of physiologically-relevant alternatives to animal testing in research and drug discovery. ACS commercial services and products are based in long-standing expertise in human and animal primary cell isolation i.e. cells freshly-isolated from donor tissue. The company’s growing cell biobank is based upon human tissue sourced as surgical excess with full ethical permission. Primary cells are incorporated into a range of cell-based services which can be used to evaluate potential therapeutics, including those from natural sources. Technology is also focused on delivering an innovative range of cell-based products deriving from these cell sources. ACS technology is extending to isolation of iPS cells, and its business is growing internationally, particularly in SE Asia, where a subsidiary company has been established.

www.avanticell.com

Required Research Experiences

  • RESEARCH FIELD
    Biological sciences
  • YEARS OF RESEARCH EXPERIENCE
    1 - 4

Offer Requirements

  • REQUIRED EDUCATION LEVEL
    Biological sciences: Master Degree or equivalent
  • REQUIRED LANGUAGES
    ENGLISH: Good

Skills/Qualifications

A suitable background for the open position includes knowledge of cell biology and the uses of cell-based analysis, and the applicant should be able to demonstrate expertise and practical skills in cell culture. In case of equal qualification, candidates with background in a commercial scientific environment will be preferred.

Experience eligibility requirement: Eligible applicants must have less than 4 years research experience (Early Stage Researcher) at the signature of the contract (measured from the time the Master’s degree has been obtained).

Eligible applicants must not have a PhD.

Specific Requirements

The cells and processes used in the project are at the leading edge of cell culture technology. ACS cells and model systems are fastidious in their culture requirements, demand use of rare, expensive medium additives and often make use of 3D culture formats. Practical experience in these specialist areas will be an advantage.

Gender : Applications from qualified female researchers are strongly encouraged.

Work location(s)
1 position(s) available at
AvantiCell Science Ltd
United Kingdom
Scotland
Ayr
KA65HW
GibbsYard, Auchincruive

EURAXESS offer ID: 189077